Afuco™ Anti-Human ADAM17 ADCC Therapeutic Antibody, ADCC Enhanced
Anti-ADAM17 ADCC Enhanced Antibody is an ADCC enhanced antibody produced by our Afuco™ platform. Anti-TACE (ADAM17) antibodies are disclosed that for the first time in the art are capable of binding to TACE, of acting as antagonists of one or more its biological activities, in particular by binding to TACE in a cross domain binding mode in which residues in both the catalytic domain and in the cysteine rich/disintegrin domains (Dis-Cys) are involved in antibody binding to TACE, helping to improve the specificity of the antibody binding and/or helping to improve inhibition of TACE biological activity. The therapeutic uses of the antibodies, in particular for the treatment of cancer are disclosed.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-014CL |
| Pricing | Inquiry |
| Host | Human |
| Target | ADAM17 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at –20 or -70°C upon receipt. Divide antibody into aliquots prior usage and avoid multiple freeze-thaw cycles. |